Skip links and keyboard navigation

Medicinal cannabis products

Current Commonwealth and State regulations are designed to ensure the supply of medicinal cannabis is safe, and to protect and help patients.

Doctors must have confidence that any substance they prescribe to help treat a patient is safe. Doctors and their patients need to know that any medical product used for treatment has a predictable and reliable effect. Users of medicinal cannabis products deserve the same certainty.

Accessing a legal product

Medicinal cannabis use is only lawful when the cultivation, manufacture, prescribing and supply complies with all applicable Commonwealth and state or territory laws. Over time, the medicinal cannabis supply will be easier to access and the cost of legal products should reduce.

Future Australian products

Once Australia has its own medicinal cannabis products that meet the safety and production standards set by the Commonwealth Government's Therapeutic Goods Administration, the Queensland Government can approve these goods for use in Queensland patients.

Access to Nabiximols (Sativex) in Queensland

Sativex is currently the only medicinal cannabis product registered in the Australian Register of Therapeutic Goods (ARTG)—it is registered for use in spasticity associated with Multiple Sclerosis (Australia). In some other countries it is used for the management of advanced cancer pain e.g. Canada.

In Queensland specialist medical practitioners (including specialist general practitioners) are able to prescribe Sativex without requiring an approval from the state or the TGA. All non-specialist medical practitioners need to apply to the Director-General Queensland Health for a Section 18 approval under the Health Drugs and Poisons Regulation 1996 (HDPR).

Complete a Request for Chief Executive Approval (PDF 398 kB).

Last updated: 1 March 2017